Paying user area
Try for free
Biogen Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Biogen Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Current ratio | = | Current assets1 | ÷ | Current liabilities1 | |
---|---|---|---|---|---|
Dec 31, 2021 | = | ÷ | |||
Dec 31, 2020 | = | ÷ | |||
Dec 31, 2019 | = | ÷ | |||
Dec 31, 2018 | = | ÷ | |||
Dec 31, 2017 | = | ÷ | |||
Dec 31, 2016 | = | ÷ | |||
Dec 31, 2015 | = | ÷ | |||
Dec 31, 2014 | = | ÷ | |||
Dec 31, 2013 | = | ÷ | |||
Dec 31, 2012 | = | ÷ | |||
Dec 31, 2011 | = | ÷ | |||
Dec 31, 2010 | = | ÷ | |||
Dec 31, 2009 | = | ÷ | |||
Dec 31, 2008 | = | ÷ | |||
Dec 31, 2007 | = | ÷ | |||
Dec 31, 2006 | = | ÷ | |||
Dec 31, 2005 | = | ÷ |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$ in thousands
- Current Assets
- Current assets showed an overall upward trend from 2005 through 2016, increasing from approximately 1.62 billion US dollars in 2005 to a peak of about 8.73 billion in 2016. Following 2016, current assets exhibited some volatility, decreasing to around 7.64 billion in 2018, then rising again to approximately 8.38 billion in 2019 before declining to 6.89 billion in 2020 and modestly recovering to 7.86 billion by 2021. This pattern suggests periods of asset growth alongside occasional reductions, possibly reflecting operational or investment activities.
- Current Liabilities
- Current liabilities displayed notable fluctuations over the observed period. Initially, liabilities hovered around 583 million in 2005 and 2006 but soared dramatically to approximately 2.19 billion in 2007. From 2007 to 2010, liabilities fluctuated, decreasing and then rising again, reaching just over 1.05 billion in 2010. Subsequent years through 2016 saw a steady increase, peaking near 3.42 billion. After 2016, current liabilities remained relatively stable until 2018, followed by significant increases in 2019 to nearly 4.86 billion, a decline in 2020, and a moderate rise in 2021 to about 4.30 billion. These variations indicate changes in short-term obligations possibly connected to operational cycles or financing decisions.
- Current Ratio
- The current ratio, a measure of short-term liquidity, demonstrated considerable variability. Starting at 2.78 in 2005, it improved slightly to 2.94 in 2006 before dropping sharply to 1.08 in 2007. From 2007 onwards, the ratio generally improved, peaking at 3.47 in 2009, suggesting strong liquidity during that period. The ratio then gradually declined to 1.72 by 2019, with minor fluctuations thereafter, remaining around 1.83 in 2021. This trend implies that although liquidity was robust in earlier years, particularly around 2009, it decreased moderately in recent years but stayed above 1, indicating the company maintained the ability to cover its short-term liabilities with current assets.
Comparison to Competitors
Biogen Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec 31, 2021 | |||||||||||||
Dec 31, 2020 | |||||||||||||
Dec 31, 2019 | |||||||||||||
Dec 31, 2018 | |||||||||||||
Dec 31, 2017 | |||||||||||||
Dec 31, 2016 | |||||||||||||
Dec 31, 2015 | |||||||||||||
Dec 31, 2014 | |||||||||||||
Dec 31, 2013 | |||||||||||||
Dec 31, 2012 | |||||||||||||
Dec 31, 2011 | |||||||||||||
Dec 31, 2010 | |||||||||||||
Dec 31, 2009 | |||||||||||||
Dec 31, 2008 | |||||||||||||
Dec 31, 2007 | |||||||||||||
Dec 31, 2006 | |||||||||||||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Biogen Inc., current ratio, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Biogen Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 | ||
Dec 31, 2012 | ||
Dec 31, 2011 | ||
Dec 31, 2010 | ||
Dec 31, 2009 | ||
Dec 31, 2008 | ||
Dec 31, 2007 | ||
Dec 31, 2006 | ||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Biogen Inc. | Health Care | |
---|---|---|
Dec 31, 2021 | ||
Dec 31, 2020 | ||
Dec 31, 2019 | ||
Dec 31, 2018 | ||
Dec 31, 2017 | ||
Dec 31, 2016 | ||
Dec 31, 2015 | ||
Dec 31, 2014 | ||
Dec 31, 2013 | ||
Dec 31, 2012 | ||
Dec 31, 2011 | ||
Dec 31, 2010 | ||
Dec 31, 2009 | ||
Dec 31, 2008 | ||
Dec 31, 2007 | ||
Dec 31, 2006 | ||
Dec 31, 2005 |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).